Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Cheng

Optometrist Cambridge, MA Doctor of Optometry

NPI 1629358346 CMS profile 864878

1 Brattle Sq, Suite A2, Cambridge, MA 02138

Open in the dashboard

General payments

$4,923

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Cheng of Cambridge, MA is reported in the CMS Open Payments database as having received $4,923 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,232 39
2024 General $913 28
2023 General $744 22
2022 General $1,209 34
2021 General $313 15
2020 General $49 3
2019 General $462 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Cheng
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Susan Cheng were reported at $1,232. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Susan Cheng Optometrist median Middle half National median
2019 $462 $159 $67–$371 $163
2020 $49 $72 $29–$165 $114
2021 $313 $125 $46–$292 $132
2022 $1,209 $162 $66–$374 $149
2023 $744 $177 $72–$406 $160
2024 $913 $188 $77–$427 $164
2025 $1,232 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Vision Care, Inc. $1,828 49 payments
  2. CooperVision Inc. $937 23 payments
  3. Tarsus Pharmaceuticals, Inc. $825 23 payments
  4. Alcon Vision LLC $568 25 payments
  5. Bausch & Lomb Americas Inc. $277 14 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $275 11 payments
  7. AbbVie, Inc. $82 3 payments
  8. Sun Pharmaceutical Industries Inc. $77 2 payments
  9. Amgen Inc. $41 2 payments
  10. Marco Ophthalmic, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,330 152 payments
  2. Consulting Fee $593 1 payment
Products named General payments · program years 2019–2025
  1. Acuvue $1,364 35 payments
  2. MyDay Contact Lens $789 20 payments
  3. XDEMVY $690 22 payments
  4. TOTAL30 $233 10 payments
  5. BIOTRUE ONE DAY $223 7 payments
  6. INFUSE $159 8 payments
  7. ULTRA $125 1 payment
  8. BIOTRUE $125 1 payment
  9. Precision7 $120 6 payments
  10. Precision 1 $118 5 payments
  11. Other $779 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$3,909

Medicare's payments for the services billed

Medicare patients

35

Average age 74

Services billed

79

22 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 43%
Cancer 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $273
$273 — —
TEPEZZA
  • Amgen Inc. $41
$41 — —
MIEBO
  • Bausch & Lomb Americas Inc. $20
$20 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $20
$20 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record